由加州大学洛杉矶分校牵头的一个新的治疗组合延长了先进的直肠癌患者的生存期,给选择有限的地方带来了希望。 A new UCLA-led treatment combo extends survival for advanced colorectal cancer patients, offering hope where options were limited.

由加州大学洛杉矶分院牵头的一项研究发现,将zanzalintinib和atezolizumab结合,与标准的regorafenib治疗相比,延长了晚期结肠癌患者的生存并改进了疾病控制。 A UCLA-led study finds that combining zanzalintinib and atezolizumab extends survival and improves disease control in advanced colorectal cancer patients compared to standard regorafenib treatment. 发表在"柳叶刀"杂志上,并在ESMO大会上发表,结果标志着首个基于免疫疗法的疗法, 显示大多数转移性结直肠癌患者的生存益处, 这是美国癌症死亡的第二大原因. Published in The Lancet and presented at the ESMO Congress, the results mark the first immunotherapy-based regimen to show a survival benefit for most patients with metastatic colorectal cancer, the second leading cause of cancer death in the U.S. 这种疗法为95%的病人提供了新的希望,这些病人以前没有MSI-H或DMMR基因标记,而以前他们的治疗选择有限。 The therapy offers new hope for the 95% of patients without MSI-H or dMMR genetic markers who previously had limited treatment options.